Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Do not make the mistake of considering psoriasis as dandruff. It is important to know the difference between scalp psoriasis ...

Phase 3 trial results released by Protagonist Therapeutics has revealed that icotrokinra, an oral IL-23 receptor inhibitor, achieved clear or nearly clear skin in 66% of patients with ...

J&J JNJ announced positive data from the phase III ICONIC-TOTAL study evaluating its investigational oral peptide, ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

may improve treatment outcomes by increasing adherence. Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body ...

The drugmaker has been working on more convenient treatment options as its injectable ... Icotrokinra helped 66% of patients with scalp psoriasis and 77% of those with genital psoriasis achieve ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital ... icotrokinra to shift the treatment paradigm in moderate-to-severe plaque psoriasis, by offering a combination ...